Clinical trials
Recurrence clinical trials
Below are recruiting recurrence clinical trials, each written for real people, not researchers. We’re tracking 1,425 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06777017Recruiting
Can liver stiffness predict cancer return after ablation?
This trial studies if measuring liver and spleen stiffness can help predict the risk of liver cancer coming back after radiofrequency ablation (RFA), a treatment that uses heat to destroy tumors. It aims to improve follow-up care for people with chronic liver disease and early-stage liver cancer.
BolognaAges 18 years+ - NCT06778603RecruitingPhase 1/Phase 2
Using B7-H3 imaging to guide osteosarcoma surgery
This trial tests a special dye that targets B7-H3, a protein found on osteosarcoma cells. Before your surgery, the dye is injected and helps surgeons see tumor edges more clearly, so they can remove all of the cancer while saving healthy tissue.
Beijing, Beijing MunicipalityAges 18–60 - NCT06781879RecruitingPhase 4
Comparing bladder medication vs surgery for returning low-grade bladder cancer
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
AalborgAges 18 years+ - NCT06785415RecruitingPhase 1/Phase 2
Study of a drug combo for relapsed multiple myeloma
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
Rochester, MinnesotaAges 18 years+ - NCT06791941Recruiting
Studying therapy resistance in recurrent head and neck cancer
This study looks at why some head and neck cancers come back after treatment. It will test tumor tissue from people having surgery to see if certain proteins (mutant p53 and YAP) are linked to treatment resistance. Your participation could help researchers understand how to better treat these cancers in the future.
Roma, RomeAges 18 years+ - NCT06795009RecruitingPhase 1
Zanzalintinib plus paclitaxel for recurrent uterine cancer
This trial combines an experimental pill called zanzalintinib with a standard chemotherapy (paclitaxel) for people with advanced or recurrent high-grade uterine cancer who have already tried platinum-based chemotherapy. The goal is to see if this combination can help shrink or control the cancer better than standard options alone.
San Francisco, CaliforniaAges 18 years+ - NCT06795074RecruitingPhase 4
Comparing coated vs non-coated balloons for recurring urethral stricture
This trial tests if a balloon coated with a drug (paclitaxel) helps prevent the urethra from narrowing again after treatment. It may be an option for people whose stricture has come back after a prior procedure.
GothenburgAges 18 years+ - NCT06800768Recruiting
PET scan for finding thyroid cancer that has returned after surgery
This trial tests a special PET scan (68Ga-FAPI) to see if it can better find thyroid cancer that has come back or spread after surgery. It may help your doctor decide on the best next steps for your care.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06801730RecruitingPhase 2
Irinotecan liposomes plus bevacizumab for recurrent glioma
This trial tests a combination of two medications—irinotecan liposomes (a chemotherapy drug wrapped in fat particles) and bevacizumab (a drug that cuts off blood supply to tumors)—for people whose glioma (a type of brain tumor) has come back or worsened after initial treatment. The goal is to see if this combination can help control the tumor.
Lishui, ZhejiangAges 18–75 - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06815406Recruiting
Removing large colon polyps: one piece vs. multiple pieces
This trial compares two ways to remove large, flat polyps (granular type) from the colon or rectum: one that removes the polyp in one piece (endoscopic submucosal dissection) and one that removes it in pieces (endoscopic mucosal resection). The goal is to see which method has a lower chance of the polyp coming back.
BolognaAges 18 years+ - NCT06815432RecruitingPhase 1
CAR T cells for recurrent glioblastoma that makes GPC3
This trial tests a treatment made from your own immune cells, called CAR T cells, which are engineered to find and attack brain tumor cells that have a marker called GPC3. It is for patients whose glioblastoma has come back and who are already scheduled to have another surgery to remove the tumor.
Houston, TexasAges 21–70 - NCT06818331RecruitingPhase 2
Electroacupuncture study for recurring brain cancer
This trial tests if a special type of electroacupuncture can help chemotherapy (paclitaxel) reach the brain more effectively in patients whose high-grade glioma has come back after surgery. The goal is to see if this combination can slow tumor growth.
China, Hangzhou City, Zhejiang ProvinceAges 18–70 - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT06826365Recruiting
Immune cells in the uterus and infertility
This study looks at immune cells inside the uterus to understand why some women have infertility or repeated miscarriages. You may join if you have had at least two miscarriages or certain benign gynecological conditions.
KrakowAges 18–45 - NCT06827717RecruitingPhase 2
Liposomal irinotecan combo for advanced Ewing sarcoma
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06835218Recruiting
Prostate cancer real-world evidence registry
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06838676RecruitingPhase 2
ACT001 for DIPG and H3K27-altered high-grade gliomas
This trial tests a drug called ACT001 for people with diffuse intrinsic pontine glioma (DIPG) or certain high-grade gliomas that have a specific genetic change (H3K27-altered). It includes two groups: one for newly diagnosed DIPG after radiation, and another for progressive or recurrent disease.
Aurora, ColoradoAges 1–39 - NCT06839144RecruitingPhase 2
Medications before surgery to slow ovarian cancer growth
This trial tests whether giving two common medications before and after surgery can slow the growth of ovarian cancer. The medications may help reduce stress signals that could make cancer spread faster during surgery.
Ramat GanAges 20–85 - NCT06840002RecruitingPhase 1/Phase 2
Targeted drug plus chemotherapy for recurrent ovarian cancer
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06850753Recruiting
En bloc removal of liver and pancreas with transplant for bile duct cancer
This trial tests a new surgical approach that removes the liver, pancreas, and bile duct all at once (and then gives a liver transplant) for people with a type of bile duct cancer that cannot be removed with standard surgery. It may help people whose cancer is limited to the liver area and who have not responded to other treatments.
OsloAges 18–70 - NCT06855069RecruitingPhase 3
A study of HS-20089 for platinum-resistant ovarian cancer
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
BeijingAges 18 years+ - NCT06856213RecruitingPhase 2
Cetuximab with or without weekly paclitaxel for head and neck cancer
This study tests whether adding the chemotherapy drug paclitaxel (Taxol) to the targeted therapy cetuximab (Erbitux) is more effective than cetuximab alone for head and neck cancer that has progressed after initial immunotherapy and chemotherapy. Researchers want to see if the combination can help shrink tumors or slow the disease.
Santiago de Compostela, A CoruñaAges 18 years+
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence?
- Yes. Clin2 currently lists 1,425 recruiting recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.